# US 2020/0270347 A1 · Antibodies binding to cd3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270347 A1
- Document ID: US20200270347A1
- Status: Published application
- Kind: A1
- Application number: 16/721,254
- Filed: 2019-12-19
- Published: 2020-08-27
- Earliest claimed: 2018-12-21
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Anne FREIMOSER-GRUNDSCHOBER; Thomas HOFER; Ralf HOSSE; Ekkehard MOESSNER; Valeria G. NICOLINI; Pablo UMAÑA; lnja WALDHAUER; Wolfgang Richter; Alexander KNAUPP; Halina TROCHANOWSKA
- Web page: https://patentgrep.com/patent/US20200270347A1

## CPC

- C07K 16/3053: {Skin, nerves, brain}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/62: comprising only variable region components
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A bispecific antibody that binds to TYRP-1 and CD3, wherein the bispecific antibody comprises (a) a first antigen-binding domain that binds to CD3 and (b) a second antigen-binding domain that binds to TYRP-1, and wherein the first antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 3, and a HCDR 3 of SEQ ID NO: 5, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 8, a LCDR 2 of SEQ ID NO: 9, and a LCDR 3 of SEQ ID NO: 10.

### Claim 38 (depends on 37)

The bispecific antibody of claim 37, wherein the second antigen-binding domain comprises (a) a VH comprising a HCDR 1 of SEQ ID NO: 15, a HCDR 2 of SEQ ID NO: 16, and a HCDR 3 of SEQ ID NO: 17, and (b) a VL comprising a LCDR 1 of SEQ ID NO: 19, a LCDR 2 of SEQ ID NO: 20 and a LCDR 3 of SEQ ID NO: 21.

### Claim 39 (depends on 38)

The bispecific antibody of claim 38, wherein (a) the first antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11, and/or (b) the second antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 22.

### Claim 40 (depends on 39)

The bispecific antibody of claim 39, wherein (a) the first antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11, and/or (b) the second antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 41 (depends on 37)

The bispecific antibody of claim 37, wherein the bispecific antibody comprises an Fc domain comprising a first subunit and a second subunit.

### Claim 42 (depends on 41)

The bispecific antibody of claim 41, wherein each of the first antigen-binding domain and the second antigen-binding domain is a Fab, and wherein:
(i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; or
(ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

### Claim 43 (depends on 41)

The bispecific antibody of claim 41, wherein the bispecific antibody further comprises a third antigen-binding domain that binds to TYRP-1, and wherein the second antigen-binding domain and the third antigen-binding domain each comprises (a) a VH comprising a HCDR 1 of SEQ ID NO: 15, a HCDR 2 of SEQ ID NO: 16, and a HCDR 3 of SEQ ID NO: 17, and (b) a VL comprising a LCDR 1 of SEQ ID NO: 19, a LCDR 2 of SEQ ID NO: 20, and a LCDR 3 of SEQ ID NO: 21.

### Claim 44 (depends on 43)

The bispecific antibody of claim 43, wherein (a) the first antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11 and/or (b) the second antigen-binding domain and the third antigen-binding domain each comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 22.

### Claim 45 (depends on 44)

The bispecific antibody of claim 44, wherein (a) the first antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11; and/or (b) the second antigen-binding domain and the third antigen-binding domain each comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 46 (depends on 43)

The bispecific antibody of claim 43, wherein (a) the first antigen-binding domain is a crossover Fab molecule, wherein the variable domains VL and VH or the constant domains CL and CH1 of the Fab light chain and the Fab heavy chain are replaced by each other and/or (b) the each of the second antigen-binding domain and the third antigen-binding domain is a conventional Fab molecule.

### Claim 47 (depends on 46)

The bispecific antibody of claim 46, wherein in the constant domain CL of the second antigen-binding domain and/or the third antigen-binding domain, the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the constant domain CH1 of the second antigen-binding domain and/or the third antigen-binding domain, the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

### Claim 48 (depends on 43)

The bispecific antibody of claim 43, wherein each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain is a Fab, and wherein the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain; and
(i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; or
(ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

### Claim 49 (depends on 37)

One or more isolated polynucleotides encoding the bispecific antibody of claim 37.

### Claim 50 (depends on 49)

A host cell comprising the one or more isolated polynucleotides of claim 49.

### Claim 51 (depends on 50)

A method of producing a bispecific antibody that binds to TYRP-1 and CD3, wherein the method comprises culturing the host cell of claim 50 under conditions suitable for the expression of the bispecific antibody.

### Claim 52 (depends on 37)

A pharmaceutical composition comprising the bispecific antibody of claim 37 and a pharmaceutically acceptable carrier.

### Claim 53 (depends on 37)

A method of treating a TYRP-1-expressing cancer in an individual, the method comprising administering to the individual an effective amount of the bispecific antibody of claim 37.

### Claim 54

A bispecific antibody that binds to EGFRvIII and CD3, wherein the bispecific antibody comprises (a) a first antigen-binding domain that binds to CD3 and (b) a second antigen-binding domain that binds to EGFRvIII, and wherein the first antigen-binding domain comprises a VH comprising a HCDR 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 3, and a HCDR 3 of SEQ ID NO: 5, and a VL comprising a LCDR 1 of SEQ ID NO: 8, a LCDR 2 of SEQ ID NO: 9, and a LCDR 3 of SEQ ID NO: 10.

### Claim 55 (depends on 54)

The bispecific antibody of claim 54, wherein the second antigen-binding domain comprises (a) a VH comprising a HCDR 1 of SEQ ID NO: 85, a HCDR 2 of SEQ ID NO: 86, and a HCDR 3 of SEQ ID NO: 87, and (b) a VL comprising a LCDR 1 of SEQ ID NO: 89, a LCDR 2 of SEQ ID NO: 90, and a LCDR 3 of SEQ ID NO: 91.

### Claim 56 (depends on 55)

The bispecific antibody of claim 55, wherein (a) the first antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11, and/or (b) the second antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 88 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 92.

### Claim 57 (depends on 56)

The bispecific antibody of claim 56, wherein (a) the first antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11, and/or (b) the second antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 88 and a VL comprising the amino acid sequence of SEQ ID NO: 92.

### Claim 58 (depends on 54)

The bispecific antibody of claim 54, wherein the bispecific antibody comprises an Fc domain comprising a first subunit and a second subunit.

### Claim 59 (depends on 58)

The bispecific antibody of claim 58, wherein each of the first antigen-binding domain and the second antigen-binding domain is a Fab, and wherein:
(i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; or
(ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

### Claim 60 (depends on 58)

The bispecific antibody of claim 58, wherein the bispecific antibody further comprises a third antigen-binding domain that binds to EGFRvIII, and wherein the second antigen-binding domain and the third antigen-binding domain each comprises (a) a VH comprising a HCDR 1 of SEQ ID NO: 85, a HCDR 2 of SEQ ID NO: 86, and a HCDR 3 of SEQ ID NO: 87, and (b) a VL comprising a LCDR 1 of SEQ ID NO: 89, a LCDR 2 of SEQ ID NO: 90 and a LCDR 3 of SEQ ID NO: 91.

### Claim 61 (depends on 60)

The bispecific antibody of claim 60, wherein (a) the first antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11 and/or (b) the second antigen-binding domain and the third antigen-binding domain each comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 88 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 92.

### Claim 62 (depends on 61)

The bispecific antibody of claim 61, wherein (a) the first antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11; and/or (b) the second antigen-binding domain and the third antigen-binding domain each comprises a VH comprising the amino acid sequence of SEQ ID NO: 88 and a VL comprising the amino acid sequence of SEQ ID NO: 92.

### Claim 63 (depends on 60)

The bispecific antibody of claim 60, wherein (a) the first antigen-binding domain is a crossover Fab molecule, wherein the variable domains VL and VH or the constant domains CL and CH1 of the Fab light chain and the Fab heavy chain are replaced by each other and/or (b) each of the second antigen-binding domain and the third antigen-binding domain is a conventional Fab molecule.

### Claim 64 (depends on 63)

The bispecific antibody of claim 63, wherein in the constant domain CL of the second antigen-binding domain and/or the third antigen-binding domain, the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the constant domain CH1 of the second antigen-binding domain and/or the third antigen-binding domain, the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

### Claim 65 (depends on 60)

The bispecific antibody of claim 60, wherein each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain is a Fab, and wherein the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain; and
(i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; or
(ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

### Claim 66 (depends on 54)

One or more isolated polynucleotides encoding the bispecific antibody of claim 54.

### Claim 67 (depends on 66)

A host cell comprising the one or more isolated polynucleotides of claim 66.

### Claim 68 (depends on 67)

A method of producing a bispecific antibody that binds to EGFRvIII and CD3, wherein the method comprises culturing the host cell of claim 67 under conditions suitable for the expression of the bispecific antibody.

### Claim 69 (depends on 54)

A pharmaceutical composition comprising the bispecific antibody of claim 54 and a pharmaceutically acceptable carrier.

### Claim 70 (depends on 54)

A method of treating an EGFRvIII-expressing cancer in an individual, the method comprising administering to the individual an effective amount of the bispecific antibody of claim 54.

### Claim 71

An antibody that binds to CD3, wherein the antibody comprises an antigen-binding domain that binds to CD3, and wherein the antigen-binding domain comprises a VH comprising a HCDR1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 3, and a HCDR 3 of SEQ ID NO: 5, and a VL comprising a LCDR 1 of SEQ ID NO: 8, a LCDR 2 of SEQ ID NO: 9, and a LCDR 3 of SEQ ID NO: 10.

### Claim 72 (depends on 71)

The antibody of claim 71, wherein the VH is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and/or a VL is at least 95% identical to the amino acid sequence of SEQ ID NO: 11.

### Claim 73

An antibody that binds to CD3, wherein the antibody comprises an antigen-binding domain that binds to CD3 comprising a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11.

### Claim 74 (depends on 71)

The antibody of claim 71, wherein the antibody further comprises a second antigen-binding domain, and wherein the second antigen-binding domain binds to a second antigen that is not CD3.

### Claim 75 (depends on 74)

The antibody of claim 74, wherein the antibody further comprises a third antigen-binding domain, and wherein the third antigen-binding domain binds to the second antigen.

### Claim 76 (depends on 74)

The antibody of claim 74, wherein the second antigen is a tumor cell antigen.

### Claim 77 (depends on 71)

One or more isolated polynucleotides encoding the antibody of claim 71.

### Claim 78 (depends on 77)

A host cell comprising the one or more isolated polynucleotides of claim 77.

### Claim 79 (depends on 78)

A method of producing an antibody that binds to CD3, wherein the method comprises culturing the host cell of claim 78 under conditions suitable for the expression of the antibody.

### Claim 80 (depends on 71)

A pharmaceutical composition comprising the antibody of claim 71 and a pharmaceutically acceptable carrier.

### Claim 81 (depends on 71)

A method of treating a disease in an individual, the method comprising administering to the individual an effective amount of the antibody of claim 71.

### Claim 82 (depends on 81)

The method of claim 81, wherein the disease is a cancer.
